Bicara Therapeutics BCAX Business Segments — Manufacturing and process development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept bcax:ClinicalOperationsAndDevelopmentExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — manufacturing and process development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — manufacturing and process development?
- Bicara Therapeutics (BCAX) reported business segments — manufacturing and process development of $14.57M in Q1 2026.
- How has Bicara Therapeutics's business segments — manufacturing and process development changed year-over-year?
- Bicara Therapeutics's business segments — manufacturing and process development increased by 45.3% year-over-year, from $10.03M to $14.57M.
- What is the long-term trend for Bicara Therapeutics's business segments — manufacturing and process development?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — manufacturing and process development has grown at a 87.9% compound annual growth rate (CAGR), from $13.5M to $47.63M.
- What does business segments — manufacturing and process development mean?
- Captures the expenditures required to scale up manufacturing processes and ensure the quality and consistency of drug product production. This includes costs for process optimization, technology transfer, and the production of clinical trial materials.